非小细胞肺癌脑转移高危因素研究进展  

Research Progress on Risk Factors of Brain Metastasis in Non-small Cell Lung Cancer

作　　者：孙爽 门玉 惠周光 Shuang SUN;Yu MEN;Zhouguang HUI(Department of Radiation Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of VIP Medical Services,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院,北京协和医学院肿瘤医院放疗科,北京100021 [2]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院,北京协和医学院肿瘤医院特需医疗部,北京100021

出　　处：《中国肺癌杂志》2022年第3期193-200,共8页Chinese Journal of Lung Cancer

摘　　要：非小细胞肺癌(non-small cell lung cancer,NSCLC)脑转移是常见的治疗失败模式,发生脑转移的NSCLC患者中位生存时间仅为1个月-2个月。预防性脑照射(prophylactic cranial irradiation,PCI)可延缓脑转移的发生,但对NSCLC患者的生存获益仍存在争议,因此,通过预测脑转移的风险筛选可能从PCI中获益的人群尤为重要。本文就NSCLC脑转移的高危因素进行综述。Brain metastasis of non-small cell lung cancer(NSCLC) is a common treatment failure mode,and the median survival time of NSCLC patients with brain metastasis is only 1 mon-2 mon.Prophylactic cranial irradiation(PCI) can delay the occurrence of brain metastasis,but the survival benefits of NSCLC patients are still controversial.It is particularly important to identify the patients who are most likely to benefit from PCI.This article reviews the high risk factors of brain metastasis in NSCLC.

关 键 词：肺肿瘤 脑转移 预防性脑照射 

分 类 号：R734.2[医药卫生—肿瘤]